Abstract 301P
Background
This study aimed to investigate the clinical implications of desaturation during the 6-min walk test (6MWT) for postoperative cardiopulmonary complications in non-small cell lung cancer (NSCLC) patients with moderately decreased lung function.
Methods
Between January 2010 and December 2019, 312 patients whose predicted postoperative value of forced expiratory volume in 1 second (ppoFEV1) or diffusing capacity of carbon monoxide (ppoDLco) were <60% while both were ≥ 30% and who had undergone lobectomy for NSCLC without induction treatment were included this study. Patients were classified into two groups based on the presence of oxygen desaturation (SpO2 <90%) during the 6MWT, and the prevalence and risk of cardiopulmonary complications were evaluated.
Results
Overall, 39 (12.5%) patients desaturated during the 6MWT. The prevalence of cardiopulmonary complications (48.7%, p = 0.007) and pulmonary complications (33.3%, p = 0.017) was significantly higher in patients who desaturated during the 6MWT than in those who did not. However, there was no significant difference in the incidence of postoperative cardiac complications between the two groups. In multivariable-adjusted analyses, the adjusted odds ratio for postoperative cardiopulmonary complications in patients who desaturated during the 6MWT was 2.34 (95% confidence interval = 1.16–4.75) compared to those who did not.
Conclusions
Oxygen desaturation during the 6MWT significantly increased the risk of post-lobectomy cardiopulmonary complications among lung cancer patients with moderately decreased lung function. Our study suggests that oxygen desaturation during the 6WMT could provide additional information when stratifying the postoperative surgical risks in NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - Let’s bring back old drugs to conquer resistance to KRAS G12C inhibitors in NSCLC
Presenter: Anisha Jain
Session: Poster viewing 04
315P - Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A single-center experience
Presenter: Luka Brcic
Session: Poster viewing 04
316P - Phase II study of ramucirumab and docetaxel for platinum-resistance NSCLC patients with malignant pleural effusion: Analysis of pleural effusion control rate
Presenter: Ryosuke Ogata
Session: Poster viewing 04
317P - A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL)
Presenter: Taichi Matsubara
Session: Poster viewing 04